Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade N/A
- Symbol (XENT)
- Company Intersect ENT, Inc.
- Price $28.24
- Changes Percentage (0%)
- Change -$0
- Day Low $28.23
- Day High $28.25
- Year High $28.25
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 05/16/2022
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.68
- Trailing P/E Ratio -10.537313432836
- Forward P/E Ratio -10.537313432836
- P/E Growth -10.537313432836
- Net Income $-159,635,000
Income Statement
Quarterly
Annual
Latest News of XENT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Yankees' Alex Verdugo is allergic to his tattoos and might start taking Dupixent shots: report
New York Yankees' Aaron Judge praises Fresno State for his MLB success. Outfielder Alex Verdugo is allergic to his tattoos, affecting his hands. Franklin Sports is working to resolve the issue with hi...
By Fox News | 1 month ago -
Olympic wrestler Catalina Axente leaves mat on stretcher after scary fall
Romanian wrestler, Catalina Axente, sustains neck injury after being thrown by American opponent, Kennedy Blades. Axente was taken off on a stretcher but appeared to be moving her limbs. Blades subdue...
By The Guardian | 1 month ago -
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Sanofi reported a strong second-quarter performance with a 3.2% increase in operating income and exceeded sales expectations, driven by the success of its blockbuster drug Dupixent....
By Yahoo! Finance | 2 months ago
